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Background: The Efficacy of statin for coronary artery disease(CAD) is already established. The long term effect of statin for patient with peripheral 
artery disease(PAD) is still unknown.
Methods: The REAL-AI (REtrospective multicenter AnaLysis of primary stenting for AortoIliac artery disease) registry was performed as a multicenter 
registry in Japan enrolling consecutive patients undergoing primary stenting for de novo aortoiliac artery stenosis. The primary endpoint was a 
composite of death/myocardial infarction (MI) /stroke, and the secondary endpoints were primary patency (defined as treated vessel without 
restenosis).
Results: Between January 2005 and December 2009, 2096 patients were enrolled.The mean follow interval was 31±15 months. 794 patients 
(37.9%) were treated with statin. Diabetes, hypertension, CAD is more frequent in statin group, and hemodialysis is more frequent in no-statin group. 
Three year cumulative incidence of primary endpoint was lower in statin group (12.5% v.s. 17.6%, p=0.0096). The incidence of all cause mortality 
(9.2% v.s. 14.4%, p=0.0042) and Stroke (2.4% v.s. 4.5%, p=0.032) were lower in statin group, but MI was similar between two groups (3.5% v.s. 
2.2%, p=0.15). There was no significant difference in primary patency between two groups (82.5% v.s. 81.7%, p=0.81).
Conclusions: Statin use for PAD patients associated with lower incidence cardiovascular event, but has almost similar effects on primary patency 
after stenting for aortoiliac artery disease.
